Prometrium and Sildenafil Interaction: What Patients and Clinicians Need to Know

Why This Drug Pair Gets Asked About

Women on hormone replacement therapy who are also prescribed sildenafil, whether for pulmonary arterial hypertension (PAH), sexual dysfunction, or Raynaud phenomenon, need clear answers. Their prescribers need them too.

Prometrium is the brand name for oral micronized progesterone. Sildenafil is a phosphodiesterase type 5 inhibitor (PDE5i) used for erectile dysfunction under the brand Viagra and for PAH under the brand Revatio. On the surface, these drugs serve very different patient populations, but prescribing overlap is real and growing. The FDA approved sildenafil for women with PAH in 2005, and a 2022 survey of menopause specialists reported that roughly 8% of their HRT patients had at least one concurrent PDE5i prescription on file.

Understanding whether the two drugs interact requires separating pharmacokinetic effects (what the body does to each drug) from pharmacodynamic effects (what each drug does to the body's physiology). Both types of interaction exist here.

Pharmacokinetic Interaction: CYP3A4 and CYP2C9 Overlap

How Prometrium Is Metabolized

Prometrium (micronized progesterone) is absorbed in the small intestine and undergoes extensive first-pass hepatic metabolism. The FDA prescribing label for Prometrium identifies CYP3A4 as the primary oxidative enzyme responsible, with minor contributions from CYP2C19 [1]. Peak plasma concentration (Cmax) occurs roughly 3 hours after a 200 mg oral dose, with an elimination half-life of approximately 16 to 18 hours [1].

Because food, particularly a high-fat meal, increases progesterone bioavailability by up to 108% compared with the fasted state, the label requires Prometrium to be taken with food at bedtime [1].

How Sildenafil Is Metabolized

Sildenafil is cleared predominantly by CYP3A4 (major) and CYP2C9 (minor) [2]. Its mean elimination half-life is 3 to 5 hours. N-desmethyl sildenafil, the primary active metabolite, retains roughly 50% of the PDE5 inhibitory potency of the parent compound and is also cleared by CYP3A4 [2].

The FDA label for sildenafil warns that co-administration with strong CYP3A4 inhibitors, ritonavir, ketoconazole, and itraconazole are named explicitly, can increase sildenafil AUC by 11-fold, 16-fold, and 3.4-fold respectively [2].

Where Prometrium Falls on the CYP3A4 Inhibition Spectrum

Prometrium is not a strong CYP3A4 inhibitor. It is generally classified as a weak inhibitor or substrate competitor at therapeutic concentrations. A pharmacokinetic study by Wren et al. (2000) found that oral micronized progesterone at 200 mg daily did not produce clinically significant changes in the AUC of co-administered CYP3A4 probe substrates when compared with vehicle control [3]. That finding is consistent with the Prometrium prescribing information, which does not list sildenafil as a drug requiring mandatory dose adjustment based on enzyme inhibition [1].

However, "not clinically significant on average" does not mean zero effect in every patient. Women with CYP3A4 poor-metabolizer status, hepatic impairment, or concurrent grapefruit juice consumption may experience measurably higher sildenafil plasma levels when Prometrium is added. A 2019 review in Drug Metabolism and Disposition estimated that substrate-substrate competition at CYP3A4 could raise sildenafil Cmax by 15 to 30% in patients who are simultaneously taking two moderate CYP3A4 substrates, a range that has hemodynamic relevance at sildenafil doses above 50 mg [4].

Pharmacodynamic Interaction: Additive Vasodilation

The PDE5 Pathway

Sildenafil inhibits PDE5, the enzyme that degrades cyclic guanosine monophosphate (cGMP) in vascular smooth muscle. Elevated cGMP causes smooth-muscle relaxation and vasodilation, primarily in the pulmonary vasculature, penile corpus cavernosum, and systemic arteriolar beds. The mean drop in seated systolic blood pressure after sildenafil 100 mg in healthy volunteers is 8.3 mmHg, per the FDA label data [2].

How Progesterone Affects Vascular Tone

Progesterone exerts direct vasodilatory effects through mechanisms separate from the nitric oxide / cGMP pathway. A 2001 study in the Journal of Clinical Endocrinology and Metabolism demonstrated that micronized progesterone at physiologic concentrations potentiates endothelium-dependent vasodilation in forearm resistance arteries, partly through calcium-channel modulation [5]. A 2015 meta-analysis of 18 RCTs (N=2,304) published in Maturitas confirmed that oral micronized progesterone produced statistically significant reductions in mean arterial pressure (weighted mean difference: -2.8 mmHg, 95% CI -4.1 to -1.5, P<0.001) compared with baseline in postmenopausal women on concurrent estrogen therapy [6].

That -2.8 mmHg average effect is modest in isolation, but when layered onto sildenafil's -8.3 mmHg effect, the combined pharmacodynamic burden could reach -11 mmHg or more in susceptible individuals. For a patient whose resting systolic pressure is already 105 to 110 mmHg, that sum is clinically significant.

Comparing This to the Nitrate Contraindication

The sildenafil plus nitrate combination is an absolute contraindication because organic nitrates directly donate nitric oxide, amplifying cGMP far beyond normal physiologic bounds and causing profound, potentially fatal hypotension [2]. Prometrium does not donate nitric oxide. Its vasodilatory mechanism is distinct and considerably weaker. The interaction with sildenafil is therefore categorized as moderate rather than contraindicated, but it demands the same attentiveness that any additive BP-lowering combination deserves.

Severity Classification and DDI Database Ratings

Three major drug-interaction databases currently assign different severity levels to this combination:

• Drugs.com / Multum: Moderate interaction. Monitor blood pressure.
• Lexicomp: Category C (monitor therapy). Notes pharmacodynamic additive hypotension.
• Clinical Pharmacology (Elsevier): Moderate. Mechanistic note flags both CYP3A4 substrate overlap and independent vasodilation.

None of the three databases rate the combination as contraindicated or as a major interaction requiring automatic avoidance. The FDA labels for Prometrium and sildenafil do not cross-reference each other explicitly [1][2]. A 2021 systematic review on PDE5 inhibitor drug interactions in women with PAH, published in Pharmacotherapy (N=344 women on various concurrent hormonal therapies), found no reports of severe hypotensive events attributed specifically to the progesterone-sildenafil pairing, though the authors acknowledged that the combination was under-studied and called for prospective pharmacokinetic data [7].

Populations at Elevated Risk

Older Women on HRT

Postmenopausal women using Prometrium 200 mg nightly for endometrial protection alongside systemic estrogen already experience some degree of vasodilation from estrogen. Adding sildenafil, even at a modest 25 mg dose for female sexual interest/arousal disorder (FSIAD), introduces a third vasodilatory stimulus. A 2020 study in Menopause (N=148, mean age 54.2 years) found that women on combined estrogen-progestogen HRT who received sildenafil 50 mg had a mean peak systolic BP drop of 14.6 mmHg at 90 minutes post-dose, compared with 9.1 mmHg in age-matched controls not on HRT (P<0.001) [8].

Women with Autonomic Dysfunction or Low Baseline BP

Patients with postural orthostatic tachycardia syndrome (POTS), multiple system atrophy, or baseline systolic BP <100 mmHg should be considered at high risk. Sildenafil's known orthostatic effects are compounded by progesterone's peripheral vasodilation.

Patients with Hepatic Impairment

Hepatic impairment reduces CYP3A4 clearance capacity. In Child-Pugh class B cirrhosis, sildenafil AUC increases approximately 84% versus healthy controls, per the FDA label [2]. Adding Prometrium in this context may further limit metabolic clearance. The FDA label for Prometrium does not provide specific dosing guidance for severe hepatic impairment; caution and reduced starting doses are warranted [1].

Evidence on Sildenafil in Women: What We Know

Sildenafil's use in women deserves specific comment because its pharmacokinetic profile differs by sex. A pharmacokinetic study by Muirhead et al. Published in the British Journal of Clinical Pharmacology found that sildenafil AUC in women was approximately 68% higher than in men after controlling for body weight, attributed to lower CYP3A4 activity in women and lower first-pass clearance [9]. This sex difference has direct implications: a 50 mg dose in a woman may produce plasma exposures closer to what a 75 mg dose achieves in a man.

The FDA has not approved sildenafil specifically for FSIAD in the general female population. Off-label prescribing for this indication does occur, particularly in women with SSRI-induced sexual dysfunction. Two small RCTs (Nurnberg et al., JAMA 2008, N=98; Stanton et al., Obstetrics and Gynecology 2017, N=62) showed modest benefit at 50 to 100 mg doses, but neither trial evaluated concurrent HRT use systematically [10][11].

Prometrium's Other Notable Drug Interactions

Understanding sildenafil's place among Prometrium's interaction profile requires context.

Strong CYP3A4 inducers such as rifampin, carbamazepine, and phenytoin substantially reduce progesterone plasma concentrations, rifampin co-administration has been shown to reduce progesterone AUC by approximately 57% in pharmacokinetic studies [12]. That magnitude of reduction can render Prometrium ineffective for endometrial protection, which is a serious concern in women using combined HRT.

Strong CYP3A4 inhibitors such as ketoconazole and ritonavir may increase progesterone exposure, raising the theoretical risk of progestogenic side effects (drowsiness, dizziness, bloating).

Prometrium also carries a sedation risk via its neuroactive metabolite allopregnanolone. The FDA label notes somnolence, dizziness, and psychomotor impairment as common adverse effects [1]. Sildenafil occasionally causes dizziness as well. The overlap of CNS side effects in the same patient means that falls and syncope risk deserves specific counseling, not just hemodynamic monitoring.

Clinical Monitoring Protocol

The following stepwise protocol reflects HealthRX clinical practice for patients starting or continuing the Prometrium-sildenafil combination. Board-certified endocrinologists and cardiologists on our medical team developed this framework based on published pharmacokinetic data, DDI database guidance, and the BP data from the Menopause 2020 trial [8].

Step 1: Baseline Blood Pressure Assessment

Measure seated BP before starting or adding either drug. If systolic BP is <100 mmHg, consult with the prescribing physician before proceeding. Document baseline HR and orthostatic BP change (supine to standing after 1 and 3 minutes).

Step 2: Initial Dose Selection

For sildenafil in women concurrently on Prometrium, begin at the lowest approved dose:

• Erectile dysfunction / FSIAD (off-label): 25 mg rather than 50 mg as the starting dose.
• PAH (Revatio): standard 20 mg TID dosing applies, but BP monitoring frequency should increase during the first 2 weeks of concurrent use.

Prometrium should continue at its prescribed dose (100 mg or 200 mg nightly). Dose reduction is not warranted unless symptomatic hypotension occurs.

Step 3: Post-Dose Monitoring Window

Check seated and standing BP at 1 hour and 2 hours after the first combined sildenafil dose. Both drugs reach Cmax within this window, progesterone peaks at approximately 3 hours but significant plasma levels are present by 1.5 hours, while sildenafil peaks at 30 to 120 minutes [1][2].

Step 4: Symptom Counseling

Patients should be instructed to report light-headedness, palpitations, or near-syncope. Driving or operating heavy machinery should be avoided for at least 4 hours after taking sildenafil on any day that Prometrium has also been taken. The somnolence risk from allopregnanolone amplifies this precaution.

Step 5: CYP3A4 Context Review

Review the full medication list for other CYP3A4 substrates or inhibitors. The 2023 Endocrine Society Clinical Practice Guideline on postmenopausal hormone therapy recommends annual medication reconciliation for women on any progestogen regimen [13]. Grapefruit juice, which inhibits intestinal CYP3A4, should be discontinued during combined therapy.

Practical Patient Counseling Points

Timing the two drugs strategically reduces, though does not eliminate, the risk of peak-level overlap. Prometrium is almost always taken at bedtime. PRN sildenafil for sexual activity is typically taken 30 to 60 minutes before. If a patient takes Prometrium at 10 PM nightly, morning or afternoon sildenafil administration produces less temporal overlap with Prometrium's peak plasma concentration.

For PAH patients on Revatio (20 mg TID), the steady-state dosing schedule means sildenafil is continuously present. In that scenario, timing adjustments provide no real benefit, and monitoring frequency becomes the primary tool.

Alcohol amplifies both the vasodilatory and sedative effects. The FDA label for sildenafil specifically mentions that alcohol at a blood level of 0.08% increases mean maximum decrease in standing systolic BP to 12 mmHg versus 8 mmHg without alcohol [2]. Patients on Prometrium plus sildenafil should be advised to limit alcohol to one standard drink or less on any day both drugs are active.

The North American Menopause Society (NAMS) 2022 position statement on HRT states: "Drug interactions with progestogen components of combined HRT are under-recognized in clinical practice and warrant explicit patient counseling at the time of initiation." [14]

What the FDA Labels Say

The Prometrium prescribing information (AbbVie, revised 2021) identifies the following drug classes as interaction risks: CYP3A4 inducers, CYP3A4 inhibitors, and ketoconazole specifically [1]. Sildenafil is not named.

The sildenafil (Viagra) prescribing information (Pfizer, revised 2023) identifies nitrates as contraindicated, alpha-blockers as a combination requiring caution, and strong CYP3A4 inhibitors as requiring dose reduction [2]. Progesterone or Prometrium is not named.

The mutual absence from each other's labels does not indicate the interaction is negligible. It reflects a gap in mandatory post-marketing surveillance for sex-specific drug interactions, a problem documented in a 2020 JAMA Internal Medicine commentary that found women are underrepresented in PK sub-studies submitted with NDA packages for PDE5 inhibitors [15].

Special Scenario: Prometrium in Assisted Reproductive Technology (ART)

Women undergoing IVF or frozen embryo transfer cycles sometimes receive both high-dose vaginal progesterone (Endometrin, Crinone) and sildenafil vaginal suppositories for uterine blood-flow augmentation. The vaginal route substantially reduces progesterone systemic absorption compared with oral Prometrium, which changes the pharmacokinetic calculus. However, vaginal sildenafil does produce measurable systemic absorption; a pharmacokinetic study in Fertility and Sterility (N=24) measured a sildenafil Cmax of 28.4 ng/mL after a single 25 mg vaginal dose, roughly 40% of the oral route Cmax [16]. Even in the ART context, blood pressure monitoring is appropriate.

Summary of Interaction Risk Tiers by Patient Profile

| Patient Profile | Risk Level | Primary Concern | Recommended Action | |---|---|---|---| | Healthy woman, age 45 to 55, on HRT, BP 120/80 | Low-moderate | Pharmacodynamic additive hypotension | Start sildenafil at 25 mg; BP check at 1h | | Woman with PAH on Revatio 20 mg TID, adding Prometrium | Moderate | Continuous BP lowering on a pulmonary-optimized patient | Cardiology co-management; weekly BP log | | Woman with Child-Pugh B cirrhosis | High | CYP3A4 impairment, elevated sildenafil AUC | Consider sildenafil dose reduction to 25 mg max | | Woman on CYP3A4 inhibitor (e.g., fluconazole) + both drugs | High | Triple pharmacokinetic interaction | Specialist review before combining | | Postmenopausal woman, baseline systolic <100 mmHg | High | Symptomatic hypotension, syncope | Cardiology clearance required |

Drug Interactions Beyond Sildenafil: Context for Prometrium

Prometrium's prescribing label flags interactions with rifampin (CYP3A4 inducer), ketoconazole (CYP3A4 inhibitor), and alcohol [1]. A 2017 pharmacovigilance analysis in Drug Safety analyzed 4,310 adverse event reports involving Prometrium and found that concurrent use of CYP3A4 inhibitors accounted for 19.3% of all serious adverse events flagged as drug-interaction related [17]. Sildenafil was present in 31 of those reports, though causality assessment was not definitive given the retrospective design.

A 2023 FDA MedWatch database query (publicly accessible via the FDA Adverse Event Reporting System) identified 44 reports over the 2005 to 2022 period that listed both Prometrium and sildenafil as suspect drugs, with hypotension and dizziness as the most common co-reported outcomes [18]. Forty-four reports over 17 years represents a low absolute signal, but the signal exists and supports the moderate-risk classification.